Randomised proof-of-concept phase II trial comparing targeted therapy based on tumour molecular profiling vs conventional therapy in patients with refractory cancer: results of the feasibility part of the SHIVA trial-Reference-Cited by-同舟云学术

Randomised proof-of-concept phase II trial comparing targeted therapy based on tumour molecular profiling vs conventional therapy in patients with refractory cancer: results of the feasibility part of the SHIVA trial

Published:2014-04-24 Issue:1 Volume:111 Page:17-24
ISSN:0007-0920
Container-title:British Journal of Cancer
language:en
Short-container-title:Br J Cancer

Author:

Le Tourneau C,Paoletti X,Servant N,Bièche I,Gentien D,Rio Frio T,Vincent-Salomon A,Servois V,Romejon J,Mariani O,Bernard V,Huppe P,Pierron G,Mulot F,Callens C,Wong J,Mauborgne C,Rouleau E,Reyes C,Henry E,Leroy Q,Gestraud P,La Rosa P,Escalup L,Mitry E,Trédan O,Delord J-P,Campone M,Goncalves A,Isambert N,Gavoille C,Kamal M

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://www.nature.com/articles/bjc2014211.pdf

Reference28 articles.

1. Amir E, Miller N, Geddie W, Freedman O, Kassam F, Simmons C, Oldfield M, Dranitsaris G, Tomlinson G, Laupacis A, Tannock IF, Clemons M (2012) Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer. J Clin Oncol 30: 587–592.

2. Andre F, Bachelot T, Campone M, Arnedos M, Dieras V, Lacroix-Triki M, Lazar V, Gentien D, Cohen P, Goncalves A, Lacroix L, Chaffanet M, Dalenc F, Mathieu MC, Bieche I, Olschwang S, Wang Q, Commo F, Jimenez M, Bonnefoi HR (2013) Array CGH and DNA sequencing to personalize targeted treatment of metastatic breast cancer (MBC) patients (pts): a prospective multicentric trial (SAFIR01). J Clin Oncol 31, (abstr 511).

3. Arkenau HT, Barriuso J, Olmos D, Ang JE, de Bono J, Judson I, Kaye S (2009) Prospective validation of a prognostic score to improve patient selection for oncology phase I trials. J Clin Oncol 27: 2692–2696.

4. Blackwell KL, Burstein HJ, Storniolo AM, Rugo HS, Sledge G, Aktan G, Ellis C, Florance A, Vukelja S, Bischoff J, Baselga J, O'Shaughnessy J (2012) Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 study. J Clin Oncol 30: 2585–2592.

5. Doroshow JH (2010) Selecting systemic cancer therapy one patient at a time: is there a role for molecular profiling of individual patients with advanced solid tumors? J Clin Oncol 28: 4869–4871.

Cited by 59 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Usefulness and real-world outcomes of next generation sequencing testing in patients with cancer: an observational study on the impact of selection based on clinical judgement;eClinicalMedicine;2023-06

2. Quo vadis precision oncology?;Journal of Cancer Research and Clinical Oncology;2023-01

3. Programmatic Precision Oncology Decision Support for Patients With Gastrointestinal Cancer;JCO Precision Oncology;2023-01

4. Biomarker-driven therapies for previously treated squamous non-small-cell lung cancer (Lung-MAP SWOG S1400): a biomarker-driven master protocol;The Lancet Oncology;2020-12

5. Bayesian cluster hierarchical model for subgroup borrowing in the design and analysis of basket trials with binary endpoints;Statistical Methods in Medical Research;2020-03-17